Form 8-K - Current report:
SEC Accession No. 0001193125-24-198969
Filing Date
2024-08-12
Accepted
2024-08-12 17:03:51
Documents
14
Period of Report
2024-08-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d883084d8k.htm   iXBRL 8-K 27853
2 EX-99.1 d883084dex991.htm EX-99.1 10076
  Complete submission text file 0001193125-24-198969.txt   161728

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA syrs-20240812.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE syrs-20240812_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syrs-20240812_pre.xml EX-101.PRE 10809
16 EXTRACTED XBRL INSTANCE DOCUMENT d883084d8k_htm.xml XML 3499
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

EIN.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37813 | Film No.: 241197806
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)